Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVKD NASDAQ:IMNN NASDAQ:PBM OTCMKTS:RSPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$2.06+1.0%$3.52$1.86▼$14.64$6.97M1.7390,309 shs71,099 shsIMNNImunon$1.53+1.3%$1.95$1.48▼$8.19$6.35M1.96226,688 shs79,059 shsPBMPsyence Biomedical$3.04+3.1%$3.34$1.92▼$68.53$6.77M1.6775,333 shs32,251 shsRSPICortex Pharmaceuticals$0.00$0.00$0.00▼$0.00N/AN/AN/AN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics+0.98%-1.44%-32.46%-61.35%-82.07%IMNNImunon+1.32%-13.56%-14.53%-44.36%-78.14%PBMPsyence Biomedical+3.05%-3.80%+2.36%-52.72%-95.77%RSPICortex Pharmaceuticals0.00%0.00%0.00%+0.00%+20.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVKDCadrenal Therapeutics$2.06+1.0%$3.52$1.86▼$14.64$6.97M1.7390,309 shs71,099 shsIMNNImunon$1.53+1.3%$1.95$1.48▼$8.19$6.35M1.96226,688 shs79,059 shsPBMPsyence Biomedical$3.04+3.1%$3.34$1.92▼$68.53$6.77M1.6775,333 shs32,251 shsRSPICortex Pharmaceuticals$0.00$0.00$0.00▼$0.00N/AN/AN/AN/AOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVKDCadrenal Therapeutics+0.98%-1.44%-32.46%-61.35%-82.07%IMNNImunon+1.32%-13.56%-14.53%-44.36%-78.14%PBMPsyence Biomedical+3.05%-3.80%+2.36%-52.72%-95.77%RSPICortex Pharmaceuticals0.00%0.00%0.00%+0.00%+20.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVKDCadrenal Therapeutics 2.00Hold$13.00531.07% UpsideIMNNImunon 2.00Hold$10.00553.59% UpsidePBMPsyence Biomedical 1.00SellN/AN/ARSPICortex Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RSPI, PBM, IMNN, and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CVKDCadrenal Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026IMNNImunon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026PBMPsyence Biomedical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVKDCadrenal TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AIMNNImunonN/AN/AN/AN/A$2.30 per shareN/APBMPsyence BiomedicalN/AN/AN/AN/A$7.39 per shareN/ARSPICortex PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVKDCadrenal Therapeutics-$13.24M-$5.63N/AN/AN/AN/A-411.03%-275.61%8/10/2026 (Estimated)IMNNImunon-$14.49M-$5.16N/AN/AN/AN/A-341.23%-153.79%8/4/2026 (Estimated)PBMPsyence Biomedical-$6.94M$25.340.12N/AN/AN/AN/AN/AN/ARSPICortex PharmaceuticalsN/A-$0.02N/AN/AN/AN/AN/AN/AN/ALatest RSPI, PBM, IMNN, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026CVKDCadrenal Therapeutics-$1.42N/AN/AN/AN/AN/A8/4/2026Q2 2026IMNNImunon-$0.8675N/AN/AN/AN/AN/A6/22/2026Q4 2026PBMPsyence BiomedicalN/A-$0.4050N/A-$0.4050N/AN/A5/12/2026Q1 2026IMNNImunon-$1.2150-$0.84+$0.3750-$0.84N/AN/A5/7/2026Q4 2025CVKDCadrenal Therapeutics-$1.51-$1.04+$0.47-$1.04N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCVKDCadrenal TherapeuticsN/AN/AN/AN/AN/AIMNNImunonN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/ARSPICortex PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVKDCadrenal TherapeuticsN/A2.682.68IMNNImunonN/A1.591.59PBMPsyence BiomedicalN/A14.6214.62RSPICortex PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVKDCadrenal Therapeutics7.92%IMNNImunon4.47%PBMPsyence Biomedical77.44%RSPICortex PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCVKDCadrenal Therapeutics26.09%IMNNImunon2.83%PBMPsyence Biomedical3.60%RSPICortex Pharmaceuticals50.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVKDCadrenal Therapeutics43.42 million2.53 millionNot OptionableIMNNImunon304.20 million4.08 millionNot OptionablePBMPsyence BiomedicalN/A2.29 million2.21 millionN/ARSPICortex Pharmaceuticals2949.46 million474.45 millionNot OptionableRSPI, PBM, IMNN, and CVKD HeadlinesRecent News About These CompaniesRespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested PartiesNovember 20, 2025 | globenewswire.comRespireRx Pharmaceuticals Inc. Announces NIH/NINDS Grant Award and Amended and Restated Patent License AgreementNovember 19, 2025 | globenewswire.comRespireRx Pharmaceuticals Inc. Announces SEC Order Making Findings and Revoking Registration of Securities and Future Plans with respect to its Common StockNovember 18, 2025 | markets.businessinsider.comRespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, ...February 10, 2025 | gurufocus.comRespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord InjuryMay 29, 2024 | globenewswire.comRespireRx Pharmaceuticals Inc (RSPI)May 23, 2024 | investing.comRespireRx Pharmaceuticals Inc RSPIMay 1, 2024 | morningstar.comMRCKT Rocket Pharmaceuticals, Inc.April 20, 2024 | seekingalpha.comRespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord InjuryMarch 20, 2024 | globenewswire.comRespireRx Pharmaceuticals shares Preclinical Pain Relief for their Non-Opioid Lead KRM-II-81March 9, 2024 | proactiveinvestors.comRespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of DirectorsJanuary 22, 2024 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic PatientJanuary 4, 2024 | finance.yahoo.comRespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business DevelopmentDecember 11, 2023 | finance.yahoo.comOther OTC Pharmaceuticals - HaitiOctober 22, 2023 | statista.comSRespireRx Pharmaceuticals subsidiary inks MSA for dronabinol manufacturingOctober 12, 2023 | proactiveinvestors.comRespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related ServicesOctober 12, 2023 | finance.yahoo.comOther OTC Pharmaceuticals - VietnamSeptember 12, 2023 | statista.comSOther OTC Pharmaceuticals - FinlandSeptember 12, 2023 | statista.comSPharmaceutical cannabis sales surge, clinical trials seeing broader disease focusAugust 30, 2023 | proactiveinvestors.comRespireRx Transferes Its Pharmaceutical Cannabinoid Program To ResolutionRxAugust 9, 2023 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRSPI, PBM, IMNN, and CVKD Company DescriptionsCadrenal Therapeutics NASDAQ:CVKD$2.06 +0.02 (+0.98%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$2.06 0.00 (-0.24%) As of 07/27/2026 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Imunon NASDAQ:IMNN$1.53 +0.02 (+1.32%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$1.56 +0.03 (+1.96%) As of 07/27/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.Psyence Biomedical NASDAQ:PBM$3.04 +0.09 (+3.05%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$3.03 -0.01 (-0.33%) As of 07/27/2026 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.Cortex Pharmaceuticals OTCMKTS:RSPI$0.0018 0.00 (0.00%) As of 07/24/2026RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now AMD’s AI Bubble Could Burst Into Explosive Upside Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? A $1.5 Billion Wake-Up Call for Every AI Company on Wall Street AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear Case Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight Apple’s Earnings Setup Puts Its Record Rally and AI Patience to the Test Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
